Gemini gains US patent for cardiovascular risk gene:
This article was originally published in Clinica
Gemini Genomics has gained a US patent for a gene that can identify a individuals with a predisposition to developing elevated levels of serum low-density lipoprotein (LDL)-cholesterol, a risk factor for cardiovascular disease. The patent is based on research conducted by scientists from the Karolinska Institute in Stockholm, Sweden, who found that specific polymorphisms in the microsomal triglyceride transfer protein (MTP) affect serum levels of LDL-cholesterol. Cambridge, UK-based Gemini has exclusive commercial rights to the gene and intends to license it to pharmaceutical and healthcare companies for the development of diagnostic and therapeutic products.
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.